Genitourinary (GU) Cancer

The Genitourinary (GU) Cancer program is focused on the development of novel treatment strategies for patients with prostate, bladder, and kidney cancer. Specifically, we seek to improve the outcome of patients with these diseases by 1) developing personalized approaches to identify patients most likely to benefit from therapy while minimizing exposure to treatment-related side effects in patients unlikely to derive benefit and 2) identifying and testing new therapeutic targets. We have assembled a large portfolio of investigator initiated clinical trials aimed at achieving these goals.